HIV Prevention Clinical Trial
Official title:
Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women
The overarching goal of this research study is to achieve a better understanding of the rectal mucosal effects of feminizing hormones in people assigned male sex at birth and currently taking feminizing hormones who have sex with men. Better understanding the rectal mucosa in this population will allow for the optimization of current biomedical HIV prevention interventions and enhance design of future interventions, including an effective HIV vaccine. This study will recruit approximately 520 transgender women who have receptive anal intercourse with men (TGWSM) and cis-gender men into one of two cohorts. Cohort 1 is a cross-sectional study and Cohort 2 is a longitudinal study; enrollment into each cohort is based on participant characteristics.
Status | Recruiting |
Enrollment | 520 |
Est. completion date | August 2025 |
Est. primary completion date | August 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 59 Years |
Eligibility | INCLUSION CRITERIA Cohort 1, TGWSM using feminizing hormone therapy - Assigned male sex at birth and currently using feminizing hormone therapy - Aged 18-59 years - Able to provide informed consent in the official language of the study site's country - HIV negative - Receptive anal intercourse with a person assigned male sex at birth at least once in lifetime - Taking feminizing hormone therapy for at least the last 6 months with no change in dose for the last 3 months (i.e. no increase or decrease) - Feminizing hormone therapy is defined as use of oral, patch, topical, or injection estrogen therapy with or without progesterone therapy in people who were assigned male sex at birth but take feminizing hormones to affirm their current gender identity - Approximately half of the cohort to be using estrogen therapy alone and half using estrogen+progesterone - Anti-androgen therapy is permissive, but dose must also be stable for the last 3 months at the time of enrollment - Willing to undergo peripheral blood and rectal biopsy sampling - Willing to abstain from receptive anal intercourse for 72 hours before and for 1 week after rectal biopsy procedure - Willing to answer sexual behavior questions Cohort 1, Cisgender Males - Assigned male sex at birth, currently identify as male gender (i.e. cisgender), man who has sex with men aged 18-59 years - Able to provide informed consent in the official language of the study site's country - HIV negative - Receptive anal intercourse with a person assigned male sex at birth at least once in lifetime - No history of taking supplemental steroids including testosterone replacement therapy in the last 12 months - Willing to undergo peripheral blood and rectal biopsy sampling - Willing to abstain from receptive anal intercourse for 72 hours before and for 1 week after rectal biopsy procedure. - Willing to answer sexual behavior questions. Cohort 2, Longitudinal study with TGWSM planning to initiate feminizing hormone therapy - Assigned male sex at birth with plans to start feminizing hormone therapy - Aged 18-59 years - Able to provide informed consent in the official language of the study site's country - Naïve to feminizing hormone therapy or no use in the last 6 months, including anti-androgen therapy. - HIV negative - Receptive anal intercourse with a person assigned male sex at birth at least once in lifetime - Plans to initiate feminizing hormone therapy in next 6 months. - Feminizing hormone therapy is defined as use of oral, patch, topical, or injection estrogen therapy with or without progesterone therapy in people who were assigned male sex at birth but take feminizing hormones to affirm their current gender identity. - Anti-androgen therapy is permissive, but participants must also be initiating estrogen therapy to be eligible. - Willing to undergo peripheral blood and rectal biopsy sampling - Willing to abstain from receptive anal intercourse for 72 hours before and for 1 week after rectal biopsy procedure. - Willing to answer sexual behavior questions. EXCLUSION CRITERIA - History of inflammatory bowel disease or other inflammatory, infiltrative, infectious or vascular condition involving the lower gastrointestinal tract that, in the judgment of the investigators, may be worsened by study procedures or may significantly distort the anatomy of the distal large bowel - Significant laboratory abnormalities at baseline visit for rectal biopsies, including but not limited to: - Hemoglobin (Hgb) = 10 g/dL - Partial thromboplastin time (PTT) > 1.5x upper limit of normal (ULN) or international normalised ratio (INR) > 1.5x ULN - Platelet count <100,000 - Any known medical condition that, in the judgment of the investigators, increases the risk of local or systemic complications of endoscopic procedures or pelvic examination, including but not limited to: - Uncontrolled or severe cardiac arrhythmia - Recent major abdominal, cardiothoracic, or neurological surgery in the last 12 months - History of uncontrolled bleeding diathesis - History of colonic, rectal, or vaginal perforation, fistula, or malignancy - History or evidence on clinical examination of ulcerative, suppurative, or proliferative lesions of the anorectal mucosa. - Use of systemic (oral/IV) antibiotics within the 4 weeks prior to rectal mucosal sampling. - Participants may be screened/enrolled who do not meet this criterion, but rectal mucosal sampling will be deferred for at least 4 weeks from last systemic antibiotic use. - Continued need for, or use during the 14 days prior to enrollment, of the following medications: - Aspirin or more than 4 doses of nonsteroidal anti-inflammatory drugs (NSAIDs) - Warfarin, heparin (low-molecular weight or unfractionated), platelet aggregation inhibitors, or fibrinolytic agents - Any form of rectally administered agent besides products (lubricants or douching) used for sexual intercourse - Continued need for, or use during the 90 days prior to enrollment, of the following medications: - Systemic immunomodulatory agents - Supraphysiologic doses of steroids with the exception of short course steroids <7 days duration at the discretion of the investigator and feminizing hormone therapy as detailed in inclusion criteria - Experimental medications, vaccines, or biologicals - Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements. |
Country | Name | City | State |
---|---|---|---|
United States | Hope Clinic | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University | National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent of Rectal Mucosal Cluster of Differentiation 4 (CD4+) T Cells Expressing C-C Chemokine Receptor Type 5 (CCR5) in Cohort 1 | The median percentage of rectal mucosal CD4+ T cells that express CCR5 will be compared between groups in Cohort 1. | Day 1 (day of rectal mucosal sampling) | |
Primary | Change in Percent of Rectal Mucosal CD4+ T cells expressing CCR5 in Cohort 2 | The median percentage of rectal mucosal CD4+ T cells that express CCR5 will be compared in Cohort 2, before hormone therapy begins and after hormone therapy. | Baseline and up to 12 months after initiation of feminizing hormone therapy | |
Primary | Production of p24 from Rectal Mucosal Explant Challenge in Cohort 1 | The median production of p24 from rectal mucosal explant challenge experiments as measured by the area under the curve will be compared between groups in Cohort 1. | Day 1 (day of rectal mucosal sampling) | |
Primary | Change in Production of p24 from Rectal Mucosal Explant Challenge in Cohort 2 | The median production of p24 from rectal mucosal explant challenge experiments as measured by the area under the curve will be compared in Cohort 2, before hormone therapy begins and after hormone therapy. | Baseline and up to 12 months after initiation of feminizing hormone therapy | |
Primary | Relative abundance of Prevotellaceae in Cohort 1 | The median relative abundance of Prevotellaceae measured from rectal mucosal secretions will be compared between groups in Cohort 1. | Day 1 (day of rectal mucosal sampling) | |
Primary | Change in Relative abundance of Prevotellaceae in Cohort 2 | The median relative abundance of Prevotellaceae measured from rectal mucosal secretions will be compared in Cohort 2, before hormone therapy begins and after hormone therapy. | Baseline and up to 12 months after initiation of feminizing hormone therapy | |
Primary | Relative abundance of Bacteroidaceae in Cohort 1 | The median relative abundance of Bacteroidaceae measured from rectal mucosal secretions will be compared between groups in Cohort 1. | Day 1 (day of rectal mucosal sampling) | |
Primary | Change in Relative abundance of Bacteroidaceae in Cohort 2 | The median relative abundance of Bacteroidaceae measured from rectal mucosal secretions will be compared in Cohort 2, before hormone therapy begins and after hormone therapy. | Baseline and up to 12 months after initiation of feminizing hormone therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03411577 -
Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program
|
N/A | |
Recruiting |
NCT03112369 -
Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use
|
N/A | |
Not yet recruiting |
NCT03642314 -
HIV Self-testing in Implementation PrEP Study
|
N/A | |
Completed |
NCT01810315 -
Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity
|
Phase 1 | |
Completed |
NCT00984971 -
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
|
Phase 1 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Active, not recruiting |
NCT03255915 -
PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)
|
Early Phase 1 | |
Active, not recruiting |
NCT05037513 -
Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky
|
N/A | |
Recruiting |
NCT05087680 -
An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South
|
N/A | |
Recruiting |
NCT05804461 -
Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico
|
N/A | |
Active, not recruiting |
NCT03148171 -
Project WERK (Wellness Encouragement Respect Kinship)
|
N/A | |
Completed |
NCT04791007 -
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
|
Early Phase 1 | |
Recruiting |
NCT05412433 -
Clinic-based HIV Identification and Prevention Project Using Electronic Resources
|
N/A | |
Active, not recruiting |
NCT03977181 -
The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms
|
N/A | |
Recruiting |
NCT05165745 -
Stick2PrEP Cisgender Women and Trans Individuals
|
N/A | |
Completed |
NCT03719053 -
Single Dose Truvada Study
|
Phase 1 | |
Recruiting |
NCT03856580 -
Long-acting Biomedical HIV Prevention in Transgender Women
|
N/A | |
Completed |
NCT02750540 -
Optimization of a Tenofovir Enema for HIV Prevention
|
Phase 1 | |
Completed |
NCT01386294 -
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
|
Phase 3 | |
Completed |
NCT00993811 -
The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
|
Phase 1 |